英国批准XOANACYL,这是欧洲第一种治疗CKD病人缺铁和高磷的药物。 UK approves XOANACYL, first drug in Europe to treat both iron deficiency and high phosphorus in CKD patients.

联合王国的MAHRA已经批准了阿韦罗亚的XOANACYL,这是一种针对缺铁和高磷水平的慢性肾脏疾病的口服治疗。 The UK’s MHRA has approved Averoa’s XOANACYL, an oral therapy for chronic kidney disease (CKD), targeting iron deficiency and high phosphorus levels. 这是欧洲第一种同时在成年人中治疗这两种病症的药物。 Approved via the International Recognition Procedure based on prior EU approval, it’s the first drug in Europe to treat both conditions simultaneously in adults. 该药物旨在改进对患有与CKD有关的新陈代谢问题的病人的治疗遵守情况和治疗结果,影响到联合王国和欧洲各地数百万人。 The drug aims to improve treatment adherence and outcomes for patients with CKD-related metabolic issues, affecting millions across the UK and Europe. 欧盟尚待最后核准,但一项积极的CHMP建议支持更广泛的准入。 Final EU approval remains pending, but a positive CHMP recommendation supports broader access.